GENFIT Answers its Investors – Episode #3 - August 3, 2026
Dear All,
Following the previous episodes of our video series dedicated to the questions you have submitted, GENFIT is continuing this format of direct dialogue with its shareholders.
In this third episode, Pascal Prigent, Chief Executive Officer of GENFIT, discusses the outlook for Iqirvo® following Ipsen’s publication of its first-half 2026 results on July 30.
The episode also addresses shareholder questions regarding elafibranor in PBC and PSC, as well as GENFIT’s non-invasive diagnostic technology for MASH.
You can watch the video by clicking on the link below:
GENFIT responds to its investors – Episode 3
English subtitles are available via the video playback settings on YouTube.
Enjoy watching,
Thank you for your interest and your confidence.
The Executive Management of GENFIT
GENFIT uses trackers (tracking pixels) in its communications that are strictly limited to email deliverability, allowing us to identify the date of the last time an email was opened in order to keep our mailing lists up to date and remove contacts who have been inactive for an extended period.
For more information about how we process your personal data, please review our Privacy Policy or contact our Data Protection Officer at:dataprivacy@genfit.com.
If you wish to no longer receive these messages you can unsubscribe.